New Causal Biomarkers of Atherosclerotic Coronary Artery Disease (ASCAD) Identified in Published Results by Aitia and G3 Therapeutics

author
1 minute, 58 seconds Read
  • Aitia’s Digital Twins based on G3’s Global Multi-omic Clinical Study Data, and Aitia’s Causal AI Technology found that triglyceride-rich LDL particle were directly causal.
  • LDL-Triglycerides could become a biomarker for ASCAD, and lead to new therapeutics.

G3 Therapeutics (a life sciences company) that uses large-scale, multi-omic, biological big data for the development of life-changing diagnostics and therapeutics, as well as Aitia (the leader in the use of Causal Artificial Intelligence and “Digital Twins”, to discover and create new drugs), announced today the results of a research project that identified new ASCAD causes.

The paper “Bayesian Network Analysis of Panomic Biological Big Data Identifies the Importance of Triglyceride-Rich LDL in Atherosclerosis Development” published in the Journal Frontiers in Cardiovascular Medicine, contains the results.

G3 Therapeutics and Aitia’s team of scientists collaborated to discover that triglyceride rich LDL particle appeared upstream of ASCAD in Digital Twin models. This suggests the causality of the triglyceride rich LDL particle. The role of triglyceride rich LDL particle was independent of LDL cholesterol content (independent of LDL C) and potential causality has been further confirmed through genetic validation based on hepatic Lipase Gene (“LIPC”) The analysis revealed that ASCAD is also affected by atherogenic lipoproteins and inflammation.

These findings suggest that LDL-TG may be a new diagnostic marker for ASCAD. It could also lead to novel treatment targets, with triglyceride rich LDL particles as the focus.

Since the 1960s, we have focused exclusively on LDL cholesterol as the only treatment target for atherosclerotic heart disease. This new discovery of LDL particles rich in triglycerides opens up previously untapped opportunities for bringing novel diagnostic and therapeutic treatments to our patients who suffer from devastating cardiovascular disease. Our discovery shows the power of combining biological big data with causal AI to bring entirely novel treatments for our patients.” said Szilard Voros, MD, CEO of G3 Therapeutics.

Colin Hill, CEO of Aitia and co-founder said: “This groundbreaking result clearly demonstrates that causal AI and Digital Twins can reveal the hidden circuitry in cardiovascular disease using large-scale multiomic data.” In a few short months, 70 years of cardiovascular biology, including LDL and PCSK9 were reconstructed without hypothesis. This allowed researchers to quickly discover new drivers for atherosclerosis, such as LDL rich in triglycerides, that have eluded them for decades. A new era of AI-driven techbio discovery has begun.”

,

Similar Posts